CAR-T Explained: How Engineered T-Cells Became a $10B Market

CAR-T therapy is a $10 billion market and growing. Carvykti from JNJ and Legend Biotech alone is tracking toward $963 million in 2026. Yescarta, Kymriah, Breyanzi, and anito-cel are all generating real revenue. But most retail investors have no idea how engineered T-cells actually work. They see a stock double on a CAR-T approval and buy the headline without understanding the mechanism.

Here is what I wish someone told me when I first heard “CAR-T.”

The problem

Your immune system can kill cancer. Tumors evolved to hide. CAR-T unhides them.

T-cells are the soldiers of your immune system. They patrol your body looking for foreign invaders, viruses, bacteria, and anything that looks wrong. They destroy it. But cancer cells are your own cells gone rogue, so the T-cells often don’t recognize them as a threat. The tumor has effectively put on a disguise.

CAR-T therapy genetically reprograms your own T-cells to see through that disguise and attack the cancer.

How CAR-T works: the 4-step pipeline

Step 1: Extract

A patient’s blood is run through a machine that separates out their T-cells. This is called leukapheresis. The rest of the blood goes back into the patient. The T-cells are shipped to a manufacturing facility.

Step 2: Engineer

This is where the science happens. Scientists use a disabled virus to insert a new gene into the T-cells. That gene codes for a chimeric antigen receptor (CAR), a synthetic protein on the T-cell surface that recognizes a specific target on cancer cells. Think of it as giving the T-cell a new set of glasses tuned to see the tumor.

For most approved CAR-T therapies, the target is BCMA (B-cell maturation antigen) for multiple myeloma or CD19 for lymphoma and leukemia. The engineered T-cell now has a receptor that locks onto that target like a key in a lock.

Step 3: Multiply

The engineered T-cells are grown in bioreactors until there are millions of them. This takes 1 to 3 weeks. This is the bottleneck. The manufacturing process is why CAR-T is slow and expensive, and it is the main reason companies are racing to build allogeneic, or “off-the-shelf,” alternatives.

Step 4: Reinfuse

The patient gets a short course of chemotherapy to make room in their immune system. Then the engineered T-cells are infused back into the patient’s bloodstream. They travel to the tumor, recognize the target, and start killing. The CAR-T cells can persist for years, providing ongoing surveillance against the cancer.

Why it costs $400,000 to $600,000 per treatment

Every CAR-T dose is custom-manufactured for one patient. You cannot mass-produce it and put it on a shelf. The vein-to-vein time, from when blood leaves the patient to when engineered cells go back in, can stretch to 4 to 6 weeks. A cancer patient waiting for CAR-T may not have that long.

The manufacturing complexity is enormous. You are growing living cells in a controlled environment, testing them for sterility and potency, and shipping a frozen product under strict cold-chain logistics. One batch failure means starting over. That is $400,000 to $600,000 of cost per treatment, and the process does not scale the way pill manufacturing does.

This is why the autologous versus allogeneic debate matters so much. Autologous CAR-T uses the patient’s own cells, which is safe but slow and expensive. Allogeneic CAR-T uses donor cells, which could be manufactured in bulk and stored like a regular drug. Nobody has an approved allogeneic CAR-T yet. When someone does, the economics change.

Which cancers CAR-T treats today

CAR-T is approved for blood cancers: multiple myeloma, certain lymphomas, and leukemia. The current approved products:

• Carvykti (JNJ / Legend Biotech) for multiple myeloma. Tracking toward $963M in 2026.
• Yescarta and Tecartus (Gilead) for lymphoma and leukemia. Gilead also has anito-cel approaching PDUFA for multiple myeloma.
• Breyanzi (Bristol Myers Squibb) for lymphoma.
• Abecma (BMY / JNJ) for multiple myeloma.
• Kymriah (Novartis) for leukemia and lymphoma.

Solid tumors are the next frontier, and nobody has cracked it yet. The problem is finding a target that exists on the tumor but not on healthy tissue. In blood cancers, BCMA and CD19 are relatively clean targets. In solid tumors, most targets are shared with healthy cells, which means CAR-T would attack the patient’s normal tissue along with the cancer.

The pipeline also extends into autoimmune disease. CAR-T targeting CD19 is being tested in lupus and other autoimmune conditions, where wiping out the B-cells that drive the disease may reset the immune system entirely.

Current market players

If you want to invest in CAR-T, here are the companies to know:

• Gilead (GILD): Yescarta, Tecartus, and anito-cel. The broadest CAR-T portfolio. Gilead bought Kite Pharma for $11.9 billion in 2017 to get into this space.
• JNJ / Legend Biotech (LEGN): Carvykti for multiple myeloma. The fastest-growing CAR-T product. JNJ recently took full control of the manufacturing.
• Bristol Myers Squibb (BMY): Breyanzi and Abecma. BMY acquired Juno Therapeutics for $9 billion in 2018.
• Novartis (NVS): Kymriah, the first-ever FDA-approved CAR-T therapy (2017).

For a stock-picking approach to the cell therapy sector, see the CAR-T stocks roundup. To understand how CAR-T stacks up against bispecific antibodies, the competing modality in myeloma, read the CAR-T vs bispecifics analysis. And for the broader immunotherapy landscape, our checkpoint inhibitors explainer covers the other major drug class.

Common mistakes

Buying the approval and ignoring the manufacturing. CAR-T approval is not the same as commercial success. Vertex and CRISPR’s Casgevy was approved for sickle cell disease in December 2023. By mid-2026, only 39 patients had been infused out of roughly 60,000 addressable. The bottleneck is manufacturing capacity and treatment center access, not FDA approval.

Ignoring safety. CAR-T has real, potentially fatal side effects: cytokine release syndrome (CRS) and neurotoxicity (ICANS). Severe CRS can land a patient in the ICU. The FDA requires a REMS program for every CAR-T product, which limits the number of treatment centers and slows uptake.

Assuming solid tumors are coming soon. Every CAR-T company talks about solid tumors in its investor deck. The data so far does not support it. Treat any solid tumor CAR-T announcement as early-stage and high-risk.

Final checklist

• Do I understand the 4-step pipeline: extract, engineer, multiply, reinfuse?
• Do I know the difference between autologous (patient’s own cells) and allogeneic (donor cells)?
• Is the target BCMA (myeloma) or CD19 (lymphoma/leukemia)?
• What is the vein-to-vein time? Shorter is better for patients and for the stock.
• Is there a manufacturing bottleneck story? If yes, expect slow uptake even after approval.
• What does the PDUFA calendar say about the next catalyst?

CAR-T is one of the most important stories in oncology. The drugs work in patients who have run out of options. The market is growing fast. But the economics are constrained by a manufacturing process that does not scale like a pill. When you invest in a CAR-T company, you are betting on both the science and the supply chain.